HTG Molecular Diagnostics (HTGM) Price Target Increased to $5.00 by Analysts at Canaccord Genuity

HTG Molecular Diagnostics (NASDAQ:HTGM) had its price target upped by investment analysts at Canaccord Genuity to $5.00 in a research report issued to clients and investors on Friday. Canaccord Genuity’s target price indicates a potential upside of 24.07% from the company’s current price.

Several other research firms have also commented on HTGM. HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research raised HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Wednesday, November 15th. Finally, ValuEngine lowered HTG Molecular Diagnostics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $4.88.

HTG Molecular Diagnostics (HTGM) traded up $1.74 on Friday, reaching $4.03. The company’s stock had a trading volume of 12,288,601 shares, compared to its average volume of 4,496,367. The firm has a market capitalization of $46.14 and a price-to-earnings ratio of -1.58. HTG Molecular Diagnostics has a 52 week low of $1.20 and a 52 week high of $13.25.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Granahan Investment Management Inc. MA raised its stake in HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 488.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 416,608 shares of the medical research company’s stock after purchasing an additional 345,798 shares during the quarter. Granahan Investment Management Inc. MA owned 3.33% of HTG Molecular Diagnostics worth $708,000 at the end of the most recent reporting period. Institutional investors own 15.15% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “HTG Molecular Diagnostics (HTGM) Price Target Increased to $5.00 by Analysts at Canaccord Genuity” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2018/01/05/htg-molecular-diagnostics-htgm-price-target-increased-to-5-00-by-analysts-at-canaccord-genuity.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply